Kihara James 4

4 · ACADIA PHARMACEUTICALS INC · Filed May 5, 2026

AI-generated summary of this filing

Updated May 5, 2026

ACADIA (ACAD) Principal Accounting Officer James Kihara Sells Shares

What Happened

James Kihara, Principal Accounting Officer of ACADIA Pharmaceuticals, had restricted stock units vest on May 1, 2026 (2,596 RSUs converted to shares) and subsequently disposed of shares to cover related tax obligations. A weighted-average open-market sale of 1,332 shares occurred on May 4, 2026, for proceeds of approximately $29,024 (avg. price $21.79; sales ranged $21.79–$21.815). The filings also report a disposition of 2,596 shares at $0 tied to the vesting/withholding process.

Key Details

Transaction dates and prices:
- 2026-05-01: RSUs converted to 2,596 shares (conversion/exercise, reported as derivative activity).
- 2026-05-01: 2,596 shares reported disposed at $0 (tax withholding in connection with RSU vesting).
- 2026-05-04: Open-market sale of 1,332 shares at a weighted avg price $21.79 (range $21.79–$21.815) for ~$29,024.
Shares owned after transaction: Not specified in the excerpt of the Form 4 provided.
Notable footnotes:
- F1/F4: These were restricted stock units (one RSU = one share) vesting in annual installments (vesting began May 1, 2024).
- F2: The sales were mandatory to cover withholding taxes related to RSU vesting and intended to comply with Rule 10b5-1(c) requirements.
- F3: Reported sale price is a weighted average; the filer can provide breakouts by trade price on request.
Filing timeliness: The Form 4 was filed May 5, 2026 for transactions on May 1 and May 4; no indication in the provided data that the filing was late.

Context

These transactions are routine for RSU vesting: RSUs converted to shares and a portion of shares were withheld or sold to satisfy tax withholding — not an independent purchase decision signaling bullishness. The derivative-code entries reflect conversion/settlement of RSUs and tax withholding rather than a market-driven bet.

Form 4

Period: 2026-05-01

PRINCIPAL ACCOUNTING OFFICER

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-05-01+2,596→ 30,461 total
Sale
Common Stock
[F2][F3]
2026-05-04$21.79/sh−1,332$29,024→ 29,129 total
Exercise/Conversion
Restricted Stock Units
[F1][F4]
2026-05-01−2,596→ 2,596 total
→ Common Stock (2,596 underlying)

Footnotes (4)

[F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
[F2]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.79 to $21.815, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
[F4]The restricted stock units vest in four equal annual installments beginning May 1, 2024.

Signature

/s/ Jennifer J. Rhodes, Attorney-in-Fact|2026-05-05

1 file